SCHEMBL4557762

SCHEMBL4557762

O=C(NCC(O)C[AsH]c1ccc(N2CCOCC2=O)c(F)c1)C1=CC(Cl)=CCC1=S

nearest known ligand 0.41

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
F10 P00742 20/20 0.41
F2 P00734 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3146428 0.88 F10 (0.45) F10
SCHEMBL3156588 0.81 F10 (0.44) F10
SCHEMBL4557761 0.81 F10 (0.62) F10F2
SCHEMBL3148052 0.81 F10 (0.40) F10
SCHEMBL3146160 0.80 F10 (0.47) F10
SCHEMBL3151799 0.80 F10 (0.50) F10
SCHEMBL3151508 0.78 F10 (0.69) F10F2
SCHEMBL3160134 0.78 F10 (0.36) F10
SCHEMBL3156175 0.78 F10 (0.44) F10F2
SCHEMBL3375924 0.78 F10 (0.44) F10F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099453-A2 COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES Bayer Schering Pharma Aktiengesellschaft (DE) 2009-09-16 EP disclosed
WO-2008052671-A2 COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-05-08 WO disclosed